Cargando…
Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors
INTRODUCTION: Regulatory T cells (Tregs) have attracted attention as a novel therapeutic target to augment the clinical efficacy of immunotherapy. We conducted phase Ia and Ib trials to examine the safety and efficacy of the anti-CCR4 antibody, KW-0761 (mogamulizumab), which may eliminate effector T...
Autores principales: | Fujikawa, Kaoru, Saito, Takuro, Kurose, Koji, Kojima, Takashi, Funakoshi, Takeru, Sato, Eiichi, Kakimi, Kazuhiro, Iida, Shinsuke, Doki, Yuichiro, Oka, Mikio, Ueda, Ryuzo, Wada, Hisashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511099/ https://www.ncbi.nlm.nih.gov/pubmed/37729184 http://dx.doi.org/10.1371/journal.pone.0291772 |
Ejemplares similares
-
Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors
por: Saito, Takuro, et al.
Publicado: (2021) -
Promising results of an anti-CCR4 antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma (ATL)
por: Utsunomiya, Atae, et al.
Publicado: (2011) -
Depletion of central memory CD8(+) T cells might impede the antitumor therapeutic effect of Mogamulizumab
por: Maeda, Yuka, et al.
Publicado: (2021) -
Humanized anti CCR4 antibody KW0761 targets HTLV-1 infected CD4+ CCR4+ and CD8+CCR4+ T cells to treat HAM/TSP
por: Yamano, Yoshihisa, et al.
Publicado: (2015) -
Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)
por: Phillips, Adrienne, et al.
Publicado: (2015)